Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19
S. A. Apostolidis, A. Sarkar, H. M. Giannini, R. R. Goel, D. Mathew, A. Suzuki, A. E. Baxter, A. R. Greenplate, C. Alanio, M. Abdel-Hakeem, D. A. Oldridge, J. R. Giles, J. E. Wu, Z. Chen, Y. J. Huang, A. Pattekar, S. Manne, O. Kuthuru, J. Dougherty, B. Weiderhold, A. R. Weisman, C. A. G. Ittner, S. Gouma, D. Dunbar, I. Frank, , E. J. Wherry
Abstract
Patients with COVID-19 present with a wide variety of clinical manifestations. Thromboembolic events constitute a significant cause of morbidity and mortality in patients infected with SARS-CoV-2. Severe COVID-19 has been associated with hyperinflammation and pre-existing cardiovascular disease. Platelets are important mediators and sensors of inflammation and are directly affected by cardiovascular stressors. In this report, we found that platelets from severely ill, hospitalized COVID-19 patients exhibit higher basal levels of activation measured by P-selectin surface expression, and have a poor functional reserve upon in vitro stimulation. Correlating clinical features to the ability of plasma from COVID-19 patients to stimulate control platelets identified ferritin as a pivotal clinical marker associated with platelet hyperactivation. The COVID-19 plasma-mediated effect on control platelets was highest for patients that subsequently developed inpatient thrombotic events. Proteomic analysis of plasma from COVID-19 patients identified key mediators of inflammation and cardiovascular disease that positively correlated with in vitro platelet activation. Mechanistically, blocking the signaling of the Fc{gamma}RIIa-Syk and C5a-C5aR pathways on platelets, using antibody-mediated neutralization, IgG depletion or the Syk inhibitor fostamatinib, reversed this hyperactivity driven by COVID-19 plasma and prevented platelet aggregation in endothelial microfluidic chamber conditions, thus identifying these potentially actionable pathways as central for platelet activation and/or vascular complications in COVID-19 patients. In conclusion, we reveal a key role of platelet-mediated immunothrombosis in COVID-19 and identify distinct, clinically relevant, targetable signaling pathways that mediate this effect. These studies have implications for the role of platelet hyperactivation in complications associated with SARS-CoV-2 infection. Cover illustration O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY One-sentence summaryThe Fc{gamma}RIIA and C5a-C5aR pathways mediate platelet hyperactivation in COVID-19
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Aberrant glycosylation of anti-SARS-CoV-2 IgG is a pro-thrombotic stimulus for platelets
A. P. Bye, W. Hoepel, … J. M. Gibbins·bioRxiv·Mar 26, 2021
- Alterations in platelet proteome signature and impaired platelet integrin αIIbβ3 activation in patients with COVID-19
L. J. Goudswaard, C. M. Williams, … I. Hers·bioRxiv·Oct 12, 2022
- SARS-CoV-2 infection induces soluble platelet activation markers and PAI-1 in the early moderate stage of COVID-19
A. O. Al-Tamimi, A. M. Yusuf, … F. Ahmad·International Journal of Laboratory HematologyPeer-reviewed·Mar 9, 2022
- Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection.
L. Ma, S. K. Sahu, … H. S. Kulkarni·bioRxiv·Feb 22, 2021
- Altered fibrin clot structure contributes to thrombosis risk in severe COVID-19
M. Wygrecka, A. Birnhuber, … K. T. Preissner·bioRxiv·Sep 17, 2021
- Dysregulated Platelet Function in Patients with Post-Acute Sequelae of COVID-19
A. Aggarwal, T. K. Singh, … S. J. Cameron·bioRxiv·Jun 18, 2023